Key Developments For BioForm Medical, Inc.
BioForm Medical, Inc. (BFRM.O) (Consolidated Issue listed on NASDAQ Global Market)
BioForm Medical, Inc. Raises FY 2010 Guidance
BioForm Medical, Inc. revised fiscal 2010 guidance and expects revenues to be approximately $70-$74 million (revised from $64-$70 million), gross profit to average approximately 82% to 85% of sales on an annual basis, with some possible fluctuation outside of this range on a quarterly basis (revised from 80% to 83%) and net loss to be less than $6 million (revised from less than $14 million). According to Reuters Estimates, analysts were expecting the Company to report revenues of $67 million and net income of $(10) million for the same period.
BioForm Medical, Inc. Issues FY 2010 Guidance; Revenue Guidance In Line With Analysts' Estimates
BioForm Medical, Inc. announced that for fiscal 2010, it expects revenues to be approximately $64-$70 million, gross profit to be approximately 80%-83% of sales, with some possible fluctuation outside of this range on a quarterly basis, net loss to be less than $14 million. According to Reuters Estimates, analysts were expecting the Company to report revenue of $66 million and net profit of $(12) million for the same period.
BioForm Medical, Inc. Receives FDA Approval For Mixing Lidocaine With RADIESSE Dermal Filler
BioForm Medical, Inc. announced U.S. Food and Drug Administration (FDA) approval for a method of mixing RADIESSE dermal filler with lidocaine, which, in clinical trials, has demonstrated an improvement in patient comfort and an increase in patient satisfaction with RADIESSE dermal filler procedures. BioForm Medical will immediately begin commercial efforts to educate physicians to use this method of mixing RADIESSE dermal filler with lidocaine.
BioForm Medical, Inc. Issues FY 2009 Outlook; Revenue Outlook In Line With Analysts' Estimates; Earnings Outlook Above Analysts' Estimates
BioForm Medical, Inc. announced that for fiscal 2009, revenues are expected to be approximately $62-64 million, gross profit is expected to be approximately 80% to 83% of sales and net loss is expected to be $21-24 million. According to Reuters Estimates, analysts were expecting the Company to report revenue of $63 million and net profit of $(26) million for the same period.
BioForm Medical, Inc. Appoints Frederick Lwee As Principal Financial Officer-Form 8-K
BioForm Medical, Inc. reported in its Form 8-K that on May 5, 2009, the Board of Directors appointed Frederick Lwee, currently the Company's Corporate Controller, to the additional position of Principal Financial Officer, effective immediately.
